D. E. Shaw & Co., Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $964,048 - $1.41 Million	45,474 New	45,474 $1.39 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $20,807 - $34,221	827 Added 2.71%	31,390 $1.12 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $723,731 - $1.18 Million	30,563 New	30,563 $776,000
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $227,572 - $414,445	8,189 New	8,189 $288,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $1.31 Million - $2.32 Million	-33,117 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $510,553 - $725,180	-8,789 Reduced 20.97%	33,117 $2.2 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $1.08 Million - $1.57 Million	-18,506 Reduced 30.63%	41,906 $2.62 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $1.01 Million - $1.47 Million	16,227 Added 36.73%	60,412 $5 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $2.72 Million - $4.02 Million	-44,414 Reduced 50.13%	44,185 $2.93 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $7.64 Million - $14.9 Million	-174,373 Reduced 66.31%	88,599 $6.8 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $5.66 Million - $8.74 Million	-170,546 Reduced 39.34%	262,972 $11.3 Million
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $6.34 Million - $10.5 Million	-242,603 Reduced 35.88%	433,518 $18.7 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $344,873 - $1.06 Million	-16,774 Reduced 2.42%	676,121 $19.5 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $1.22 Million - $3.16 Million	-43,341 Reduced 5.89%	692,895 $44 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $7.42 Million - $9.85 Million	282,631 Added 62.31%	736,236 $20.7 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $1.49 Million - $2.47 Million	-85,553 Reduced 15.87%	453,605 $12 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $6 Million - $10 Million	497,972 Added 1209.08%	539,158 $9.89 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $290,742 - $533,298	-27,071 Reduced 39.66%	41,186 $512,000
Q3 2018 Nov 14, 2018	SELL	$14.0 - $20.3 $639,128 - $926,735	-45,652 Reduced 40.08%	68,257 $1.31 Million
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $4.96 Million - $10.9 Million	-777,875 Reduced 87.23%	113,909 $1.55 Million
Q1 2018 May 15, 2018	SELL	$3.72 - $7.64 $1.03 Million - $2.11 Million	-276,095 Reduced 23.64%	891,784 $6.43 Million
Q4 2017 Feb 14, 2018	BUY	$3.14 - $4.5 $615,788 - $882,499	196,111 Added 20.18%	1,167,879 $4.3 Million
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $1.64 Million - $4.21 Million	971,768	971,768 $4.21 Million

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

92.3M

Call Options Held

1.33M

Put Options Held

549K

Black Rock Inc. New York, NY

15.7M
Shares

$295 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

12.2M
Shares

$230 Million
0.01% of portfolio
Avoro Capital Advisors LLC New York, NY

8.89M
Shares

$167 Million
3.15% of portfolio
State Street Corp Boston, MA

5.84M
Shares

$110 Million
0.01% of portfolio
Slate Path Capital LP New York, NY

4.14M
Shares

$77.9 Million
2.11% of portfolio

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.99B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account